Current Report Filing (8-k)
17 March 2023 - 07:25AM
Edgar (US Regulatory)
0001710340 false 0001710340 2023-03-16
2023-03-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
March 16, 2023
Eton Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in its Charter)
|
Delaware |
|
001-38738 |
|
37-1858472 |
|
(State
or Other Jurisdiction |
|
(Commission |
|
(IRS
Employer |
|
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
|
21925 W. Field Parkway,
Suite 235
Deer Park,
Illinois
|
|
60010-7278 |
|
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(847)
787-7361
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
|
Common Stock, $0.001 par value per share |
|
ETON |
|
NASDAQ Global Market |
Item
2.02. Results of Operations and Financial Condition
On
March 16, 2023, Eton Pharmaceuticals, Inc. issued a press release
announcing its financial results for the fourth quarter and year
ended December 31, 2022. A copy of the press release is attached
hereto as Exhibit 99.1.
The
information in this Item 2.02 and the attached Exhibit 99.1 are
being furnished and shall not be deemed “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section. The
information in this Item 2.02 and the attached exhibit shall not be
incorporated by reference into any registration statement or other
document pursuant to the Securities Act of 1933, as
amended.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
Eton
Pharmaceuticals, Inc. |
|
|
|
|
Date:
March 16, 2023 |
/s/
James Gruber |
|
|
James
Gruber |
|
|
Chief
Financial Officer and Secretary |
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From May 2023 to Jun 2023
Eton Pharmaceuticals (NASDAQ:ETON)
Historical Stock Chart
From Jun 2022 to Jun 2023
